StreetAlpha.app
Home › Stocks › TNXP

Tonix Pharmaceuticals Holding Corp. (TNXP)

Healthcare
$2.94
▲ +2.08%
LAST CLOSE · NOV 17

Tonix Pharmaceuticals develops and sells prescription medicines for fibromyalgia and acute migraine. It last closed at $2.94 on Nov 17, up 2.08% on the day.

AI Auto Pilots
Is TNXP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$43.0M
+318.0% vs a year ago
Net income
−$181.0M
−420.4% margin
EPS (diluted)
−$12.39
−104.4% vs a year ago
Free cash flow
−$170.0M
−395.0% margin
Valuation
Market cap
$57.1M
19.4M shares
P/E
–
No P/E while losing money
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$162.8M
At Sep 30
Shareholder equity
$199.5M
Shares outstanding
19.4M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $7.8M$7.8MFY2023FY2024: $10.1M$10.1MFY2024FY2025: $13.1M$13.1MFY2025

From TNXP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated TNXP in the past 90 days, not enough for a consensus
Average 12-month target
$18.00
▲ 512.2% upside

Based on 1 analyst who set a price target on TNXP in the past 90 days. The average target is $18.00, with a high of $18.00 and a low of $18.00, compared with the last close of $2.94.

Low $18.00Avg $18.00High $18.00
Blue marker: last close $2.94
Highest target$18.00
Average target$18.00
Lowest target$18.00
Latest rating changes
Canaccord GenuityInitiated
Oct 26Buy$18
Raymond JamesInitiated
Jun 25Buy$26
TD CowenInitiated
May 4Buy$22
DateFirmActionRatingPrice target
Oct 26Canaccord GenuityInitiatedBuy$18
Jun 25Raymond JamesInitiatedBuy$26
May 4TD CowenInitiatedBuy$22
Loading…

Technical Analysis

TNXP · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 56% below its 20 day and 149% below its 50 day average. It is 296% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 13), oversold. The nearest support is the Pivot at $2.92, and the nearest resistance the Pivot R1 at $3.01.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.7%/day
Key levels
$20.5652 week high+599.3%
$11.65200 day average+296.3%
$9.72100 day average+230.6%
$7.3150 day average+148.6%
$5.38Swing high (Nov 4)+83.0%
$4.5720 day average+55.4%
$3.01Pivot R1+2.4%
$2.94Last close
$2.92Pivot−0.7%
$2.86Pivot S1−2.7%
$2.8152 week low−4.4%
Indicators
RSI (14)12.71Oversold below 30Oversold
MACD-1.16Below its signal lineBearish
Stochastic3.9Near the bottom of its rangeOversold
ADX (14)69.5Strong downtrend
Williams %R-95.2Oversold below −80, overbought above −20Oversold
CCI (20)-155.2Oversold below −100, overbought above 100Oversold
Rate of change−43.4%Change over 10 sessionsBearish
ATR (14)$0.43Typical daily range, 14.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TNXP

What happened before

See how TNXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in TNXP in the last 90 days.

Loading…

See today’s whale options flow across the market →

TNXP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲63 buying vs 42 selling
  • ▲Held by funds +3.6 pts
  • ▲Funds holding +10
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding113103+9.7%
In funds' top 1000–
Held by funds51.8%48.3%+3.6 pts
New / increased22 / 4128 / 49−18.2%
Reduced / sold out29 / 138 / 5+223.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TNXP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TNXP is in one of them and how their past TNXP trades turned out.

TNXP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TNXP in an article yet. Here's the latest on the wider market.

About Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals is a biopharmaceutical company based in Berkeley Heights, New Jersey. It sells TONMYA, a sublingual medicine for fibromyalgia in adults that is designed for bedtime use, along with two prescription sumatriptan products for acute migraine. Its main customers are prescribers in rheumatology, primary care, pain management and neurology practices, reached through national wholesalers and specialty distributors. The company also develops treatments for central nervous system disorders, immunology, infectious diseases and rare diseases.

Headquarters
Berkeley Heights, NJ